Welcome to our dedicated page for Clearpoint Neuro news (Ticker: CLPT), a resource for investors and traders seeking the latest updates and insights on Clearpoint Neuro stock.
ClearPoint Neuro, Inc. (Nasdaq: CLPT) is a medical device company focused on device, cell, and gene therapy-enabling technologies for precise navigation to the brain and spine. This news page aggregates company-issued updates and market-moving announcements related to ClearPoint Neuro’s neurosurgical navigation systems, laser therapy platforms, intracranial fluid management technologies, and central nervous system drug delivery services.
Readers can follow earnings and financial updates, such as preliminary unaudited revenue results and quarterly reports furnished via Form 8-K, which outline trends in biologics and drug delivery revenue, neurosurgery navigation and therapy revenue, and capital equipment and software sales. News items also cover strategic transactions, including the completed acquisition of IRRAS Holdings, Inc., which adds the IRRAflow active fluid-exchange system and expands ClearPoint Neuro’s presence in neurocritical care and intracranial bleeding management.
ClearPoint Neuro’s news flow frequently highlights regulatory milestones like FDA 510(k) clearances, including expanded MRI compatibility for the ClearPoint Prism Neuro Laser Therapy System, and international regulatory approvals that extend product use to additional countries. The company also reports on clinical and scientific developments, such as Phase I–II study results in glioblastoma and grade 4 astrocytoma using ClearPoint Prism, as well as the development and demonstration of its proprietary Robotic Neuro-Navigation System.
Investors and observers can also track partnership and conference activity, including updates on more than 60 active biopharma partners, participation in global healthcare conferences, and progress at ClearPoint Advanced Laboratories. Bookmark this page to review historical and ongoing CLPT news related to neurosurgical devices, therapy delivery platforms, and the company’s role in enabling cell and gene therapy programs.
ClearPoint Neuro, Inc. (Nasdaq: CLPT) announced its participation in upcoming investor conferences. Management will present at the 2022 Stifel Healthcare Conference on November 15, 2022, at 10:55 a.m. ET in New York, and at the 34th Annual Piper Sandler Healthcare Conference on November 29, 2022, at 11:50 a.m. ET, also in New York. ClearPoint Neuro focuses on enabling therapies for complex neurological disorders, with its navigation system having FDA clearance and operational at over 60 sites globally.
ClearPoint Neuro reported third-quarter 2022 revenue of $5.1 million, reflecting a 13% year-over-year increase. Key achievements include the European Commission granting full marketing authorization for Upstaza, a gene therapy, and multiple FDA clearances for new products. The company anticipates full-year revenues between $21.0 million and $22.0 million. However, operating expenses rose to $7.5 million, attributed to increased headcount and share-based compensation, leading to a decrease in cash reserves from $54.1 million at the beginning of the year to $40.5 million.
ClearPoint Neuro, Inc. (Nasdaq: CLPT) is set to release its financial results for Q3 2022 on November 8, 2022, after market close. A live broadcast of the results will occur at 4:30 p.m. Eastern time the same day. Investors can access the call online or by phone. ClearPoint's current offerings include advanced navigation and delivery systems for treating neurological disorders, and the company maintains partnerships with over 45 organizations in clinical trials. Investors are reminded of uncertainties affecting future performance, including market acceptance and supply chain issues.
ClearPoint Neuro, Inc. (Nasdaq: CLPT) announced that its Swedish partner, Clinical Laserthermia Systems (CLS), has received 510(k) clearance for its laser, facilitating the launch of the ClearPoint Prism™ Neuro Laser Therapy System. This system, designed for soft tissue necrosis through MRI-guided thermal therapy, combines the ClearPoint navigation platform and CLS laser technology. Currently, it is in limited market release across select U.S. academic medical centers. ClearPoint aims to enhance treatment accessibility for neurological diseases through this innovative solution.
ClearPoint Neuro, Inc. (Nasdaq: CLPT) announced the appointment of Mazin Sabra as Chief Operating Officer, effective October 10. Reporting to CEO Joe Burnett, Sabra brings extensive experience in quality, procurement, and supply chain management from Philips and Stryker. His leadership is anticipated to strengthen ClearPoint's operational infrastructure and enhance confidence among pharma and device partners. ClearPoint Neuro is dedicated to delivering therapies for neurological disorders and has a robust product portfolio including the ClearPoint Neuro Navigation System.
ClearPoint Neuro announced 510(k) clearance for version 2.1 of its Neuro Navigation software, enhancing stereotactic guidance for neurological procedures within MRI environments. This update includes improved usability for clinicians, new trajectory planning tools, and enhanced visualization capabilities. Currently in limited market release, the software will first be available to customers in the ClearPoint 'Pathfinder' Program. The company aims to optimize clinical workflows and support future innovations in preoperative planning and medical imaging.
ClearPoint Neuro reported a record quarterly revenue of $5.2 million for Q2 2022, reflecting a 52% year-over-year growth. The company reaffirmed its full-year revenue outlook of $21.0 to $22.0 million. Significant gains were seen in biologics and drug delivery revenue, which rose by 73% to $2.4 million. Operating expenses increased to $7.5 million from $5.7 million due to higher headcount and product development costs. As of June 30, 2022, cash and short-term investments totaled $45.1 million.
ClearPoint Neuro, Inc. (Nasdaq: CLPT) has received 510(k) clearance for its ClearPoint Maestro™ Brain Model, enhancing its portfolio for brain navigation and therapy delivery. The software automates MRI analysis, facilitating the identification and quantification of brain structures. Developed over a decade, it ensures sub-millimeter accuracy and is supported by extensive research. ClearPoint aims to integrate this tool into its navigation system, enhancing functionality for targeted therapies. The product release is expected to contribute significantly to clinical applications in neurosurgery.
ClearPoint Neuro (Nasdaq: CLPT) has appointed Mary McNamara-Cullinane as Vice President of Regulatory Affairs, strengthening its leadership team. With over 25 years in healthcare, she brings expertise in regulatory and clinical affairs critical for the company’s growth strategy involving new product launches and geographic expansion. CEO Joe Burnett expressed confidence in her ability to enhance the company's regulatory strategy, essential for supporting its portfolio of partners. ClearPoint aims to improve patient outcomes by delivering precise therapies for complex neurological disorders.
ClearPoint Neuro, Inc. (CLPT) will release its second-quarter financial results for 2022 on August 9, 2022, post-market close. A live broadcast will follow the announcement at 4:30 p.m. Eastern time. ClearPoint Neuro specializes in enabling therapies for complex neurological disorders. The company's ClearPoint Neuro Navigation System has received FDA clearance and is deployed in over 60 active sites globally. The press release also includes a caution regarding forward-looking statements and potential risks associated with the company's operations influenced by the COVID-19 pandemic and market acceptance.